ETF overview
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Fund facts
- Expense ratio
- 0.58%
- Fund assets
- 561.32M USD (all share classes)
- Issuer
- Invesco
- Inception date
- Jun 23, 2005
- Number of holdings
- 30
Breakdown
Holdings (30)
| Name | Ticker | Weight |
|---|---|---|
| AbbVie Inc | ABBV | 5.91% |
| Gilead Sciences Inc | GILD | 5.86% |
| Pfizer Inc | PFE | 5.71% |
| Eli Lilly & Co | LLY | 5.62% |
| Amgen Inc | AMGN | 5.43% |
| Merck & Co Inc | MRK | 5.14% |
| Johnson & Johnson | JNJ | 5.14% |
| Abbott Laboratories | ABT | 4.99% |
| Perrigo Co PLC | PRGO | 3.60% |
| Viatris Inc | VTRS | 3.44% |
| and 17 more | ||
Similar ETFs
- First Trust Nasdaq Pharmaceuticals ETFFTXH · Overlap 55% · Expense ratio 0.60%
- Portfolio Building Block World Pharma and Biotech Index ETFPBPH · Overlap 40% · Expense ratio 0.13%
- iShares U.S. Healthcare ETFIYH · Overlap 38% · Expense ratio 0.37%
- State Street Health Care Select Sector SPDR ETFXLV · Overlap 38% · Expense ratio 0.08%
- State Street SPDR S&P Pharmaceuticals ETFXPH · Overlap 37% · Expense ratio 0.35%
- iShares U.S. Pharmaceuticals ETFIHE · Overlap 37% · Expense ratio 0.37%
- Vanguard Health Care ETFVHT · Overlap 37% · Expense ratio 0.09%
- Fidelity MSCI Health Care Index ETFFHLC · Overlap 36% · Expense ratio 0.08%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
- Expense ratio
- 0.58%
- Fund assets
- 561.32M USD (all share classes)
- Issuer
- Invesco
- Inception date
- Jun 23, 2005
- Number of holdings
- 30
| Name | Ticker | Weight |
|---|---|---|
| AbbVie Inc | ABBV | 5.91% |
| Gilead Sciences Inc | GILD | 5.86% |
| Pfizer Inc | PFE | 5.71% |
| Eli Lilly & Co | LLY | 5.62% |
| Amgen Inc | AMGN | 5.43% |
| Merck & Co Inc | MRK | 5.14% |
| Johnson & Johnson | JNJ | 5.14% |
| Abbott Laboratories | ABT | 4.99% |
| Perrigo Co PLC | PRGO | 3.60% |
| Viatris Inc | VTRS | 3.44% |
| and 17 more | ||
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
- First Trust Nasdaq Pharmaceuticals ETFFTXH · Overlap 55% · Expense ratio 0.60%
- Portfolio Building Block World Pharma and Biotech Index ETFPBPH · Overlap 40% · Expense ratio 0.13%
- iShares U.S. Healthcare ETFIYH · Overlap 38% · Expense ratio 0.37%
- State Street Health Care Select Sector SPDR ETFXLV · Overlap 38% · Expense ratio 0.08%
- State Street SPDR S&P Pharmaceuticals ETFXPH · Overlap 37% · Expense ratio 0.35%
- iShares U.S. Pharmaceuticals ETFIHE · Overlap 37% · Expense ratio 0.37%
- Vanguard Health Care ETFVHT · Overlap 37% · Expense ratio 0.09%
- Fidelity MSCI Health Care Index ETFFHLC · Overlap 36% · Expense ratio 0.08%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free